New combo aims to shrink MALT lymphoma with less radiation damage

This phase 2 trial is testing a new approach for adults with stage I-II MALT lymphoma, a slow-growing cancer of the lymph nodes. Participants first receive a very low dose of radiation (4 Gy total) over two days, then take a daily targeted drug called orelabrutinib for up to 6 months. The goal is to see if this combination can effectively control the disease while reducing long-term side effects like dry mouth or cataracts that can occur with standard radiation. About 60 people will take part, and they will be followed for at least 3 months to check how well the treatment works and how safe it is.